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Introduction
Chikungunya virus (CHIKV) has been an enigma for decades before the 2005 epidemic in India
and 2015 in the Western Hemisphere. CHIKV infects 1.1 million people per year in 113
countries around the world. (Yactayo, Staples, Millot, Cibrelus, & Ramon-Pardo, 2016).
Chikungunya virus is an arbovirus spread through Aedes albopictus and Aedes aegypti
mosquito vectors. The name ‘chikungunya’ means ‘that which bends up’ termed after the
assumed posture of suffering patients. Patients who are infected with CHIKV could contract lifealtering arthralgia and myalgia. As of today, there is no cure, treatment, or vaccine for most
alphaviruses.
Chikungunya virus is an enveloped positive-sense single-stranded RNA virus with an incubation
period of 1 to 12 days. Recent research on CHIKV indicates human macrophages contribute to
successful virus replication. A rapid immune response is stimulated after the virus is transferred
to a human. In response, macrophages begin phagocytosing CHIKV, which induces
macrophage apoptosis. Macrophages infected with CHIKV experience increased expression of
MHC and co-stimulatory molecules (Nayak et al., 2017). The sudden apoptosis of the strained
macrophage catalyzes the spread of the virus in the body. The question that remains is when,
during the course of infection, does the macrophage generate apoptosis signals?
Understanding when the infection tipping point occurs can provide additional insight into the
underlying mechanisms of pathogenesis for Chikungunya virus, enabling the development of

effective prophylactics, therapeutics, and/or vaccines.

Methods
U937* cells were propagated with FBS, Penicillin/Streptomycin, L-glutamine, and HEPES
buffer. The cells were then cultured in T-75 culture flasks at 37⁰C. Monocytes were transferred

Results
Figure 1 and Figure 2 display the results from the differential gene expression analysis. Critical genes that are
impacted by the virus include GNAL 2774 (Golf) and OR4C (R membrane) of the Olfactory pathway 24 hours postinfection. While AGER 177(RAGE) and MAPK (ERK1/2, p38, and JNK) were modulated in the AGE pathway at 48
hours post-infection.
Results from further pathway analysis indicated that four pathways are impacted at the 24h timepoint (Table 1) and
235 pathways are impacted at the 48h. The top-ranking seven pathways that are impacted at 48 hpi were sorted by
Bonferroni-corrected p-value and are displayed in Table 2. Afterward, we cross-referenced human proteins within
each signaling pathway against a database with existing drug targets. Table 3 includes the top five therapeutic drug
results and the pathways that they affect. Our ranked results indicated that Telmisartan, Sunitinib, Etanercept,
Vorinostat, Dasatinib, and Regorafenib are potential therapeutic drugs to treat an infection with Chikungunya virus.

Conclusions
Our ranked results indicated that Telmisartan, common name Micardis, modulates the AGE-RAGE signaling
pathway at 48hpi. Sunitinib, market name Sutent, modulates the cytokine-cytokine receptor interaction at 24hpi and
the Ras signaling pathway at 48hpi. Etanercept, common name Enbrel, is a Dimeric fusion protein with
extracellular ligand-binding to TNFR. Enbrel’s primary use is treating a variety of inflammatory conditions including
rheumatoid arthritis. Vorinostat, market name Zolinza, influences Alcoholism signaling pathway at 24h and Chronic
myeloid leukemia pathway at 48h. Dasatinib, trade name SPRYCEL, impacts the Fc epsilon RI signaling pathway,
Chronic myeloid leukemia, Fc gamma R-mediated phagocytosis, and Ras signaling pathway at 48h. Regorafenib,
common name Stivarga, modulates Influenza A, Salmonella infection, Fc epsilon RI signaling pathway, Chronic
myeloid leukemia, AGE-RAGE signaling pathway in diabetic complications, and Ras signaling pathway all at 48h
post-infection. These results provide direction in the pursuit of potential treatments for Chikungunya infection.
These therapeutics will require validation experiments to augment ongoing efforts to develop an effective
prophylactic or therapeutic treatment for CHIKV.

Gene map of infected with CHIKV in AGE-RAGE Pathway 48hpi

to 6-well tissue culture plates with macrophage cells and incubated for 24 hours. The CHIKVLR* strain was diluted and incubated to allow virus infection. PMA-differentiated U937
macrophages were infected using CHIKV-LR and incubated at 37⁰C with 5% CO2 for two

hours. Duplicate samples were taken from mock-infected and infected monocyte-derived
macrophages at 24 and 48 hours post-infection (hpi), after which RNA was extracted and
stored. An Illumina NovaSeq instrument housed at Intermountain Precision Genomics in St.

Gene map of infected with CHIKV in Olfactory Pathway 24hpi

George, Utah synthesized the cDNA, prepared the libraries, and generated 30-60 million RNAsequencing reads for each of the duplicate samples. The fastq files representing the RNAsequencing data were then subjected to analyses including differential gene expression (DEG),
enriched functional annotations, and modulated intracellular signaling pathways. The
automated Snakemake-based ARMOR computational workflow program was used to produce
DEG results using edgeR, functional enrichment using Camera, gene isoform usage with

DRIMSeq, and visualization using R Shiny.
The significant results from the differential gene expression analysis identified host transcripts
that were influenced during CHIKV infection. These results were subjected to a pathway
enrichment analysis using SPIA. The pathway results from KEGG, Reactome, NCI, BioCarta,
and Panther yielded significant p-values, and predicted effect on 234 pathways regulation was
impacted at 48 hours post-infection. The regulatory patterns from these analyses were then
used to predict existing drugs that could be used as therapeutics for CHIKV, which generated a
list of 136 different drugs.
To reduce the results several statistical strategies were implemented. For this study, only small
molecule results were taken into consideration (except for Etancerpt). To simplify and
demonstrate the variables that were considered in the ranking of the results, a numerical grade
was assigned to each result and is included in Table 3. Requirements include but are not
exclusive to whether the drug has been through clinical trials or has FDA approval. Toxicity of
the drugs was determined by FD50 values if they were provided, if not, toxicity was determined
from recommended diet restrictions, developers’ safety statements, requirements of
administration, and long-term impacts or risks that are included in drug consumption
(numerically 0-10, 0 being the most toxic). If previously published sources indicated a
correlation between the drug and CHIKV this was included in the drug ranking.
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